Trodelvy (sacituzumab govitecan-hziy) is an intravenous infusion used to treat adults with metastatic triple-negative breast cancer who have tried at least two other treatments. Here are some key points about Trodelvy:

- Common Side Effects: Nausea, neutropenia (low white blood cell count), diarrhea, fatigue, anemia (low Show Full Answer

Trodelvy (sacituzumab govitecan-hziy) is an intravenous infusion used to treat adults with metastatic triple-negative breast cancer who have tried at least two other treatments. Here are some key points about Trodelvy:

- Common Side Effects: Nausea, neutropenia (low white blood cell count), diarrhea, fatigue, anemia (low red blood cell count), vomiting, hair loss, constipation, rash, decreased appetite, and abdominal pain.
- Serious Side Effects: Severe hypersensitivity reactions, very low white blood cell counts, severe nausea and vomiting, and fetal harm.

For more details, you can visit the following resources:
- [Trodelvy — Gilead](https://trodelvy.com)
- [Trodelvy — Breastcancer.org](https://www.breastcancer.org/treatment/targeted)

If you have any specific questions or need more information, feel free to ask!

 This AI-generated response comes from MyBCTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Trodelvy (Sacituzumab govitecan-hziy) for Breast Cancer | MyBCTeam

Triple-Negative Breast Cancer Recurrence Rate: 8 Things to Know | MyBCTeam